Sign In
Buy SXTP
$1.45
-0.0200 (-1.36%)
At Close: Jun 03, 2026
60 Degrees Pharma opens enrollment at Mount Sinai for its B-FREE trial testing tafenoquine in chronic babesiosis, addressing a major unmet medical need.
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
01:51pm, Thursday, 13'th Nov 2025
60 Degrees Pharma reports 223% YoY revenue growth in Q3 2025; advances babesiosis programs with Tulane, Mount Sinai, and MUMS canine designation plans.
Breakthrough Therapy Designation request has been submitted to FDA Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA) Re
60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
07:04am, Thursday, 09'th Oct 2025
Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition A $5K donation from the Company was split between ILADEF and GLA to recognize the winning
60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
08:02am, Wednesday, 03'rd Sep 2025
WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new
60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
08:31am, Thursday, 21'st Aug 2025
60 Degrees Pharma CEO Dr. Geoff Dow will present Sept 10 at HCW 27th Global Investment Conference; webcast and replay available on company's investor site.
90-day trial measuring change in general fatigue in chronic babesiosis patients Enrollment expected to commence Q4 2025 and to be completed by Q2 2026 Site has clinical expertise in infectious disease
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
04:14pm, Wednesday, 13'th Aug 2025
A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March
60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering
04:01pm, Wednesday, 16'th Jul 2025
WASHINGTON, July 16, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the “Company” or “60 Degrees”) (Nasdaq: SXTP; SXTPW), a pharmaceutical company focused on developing new medicin
60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering
09:10am, Tuesday, 15'th Jul 2025
60 Degrees Pharma (SXTP) prices $5M public offering with potential $5M from warrant exercise; funds to support working capital and corporate purposes.
New Drug Application intended for 2026, subject to generation of positive data from three U.S. clinical trials planned or in progress Total addressable market (TAM) for ARAKODA for Human Babesiosis is
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
08:56am, Wednesday, 04'th Jun 2025
New 8-count bottles now available through major retail pharmacies ARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June
Insurance claims show U.S. babesiosis incidence may be 10x CDC estimates; 60 Degrees links chronic fatigue and plans 2026 NDA for tafenoquine treatment.
60 Degrees Pharmaceuticals Announces First Quarter 2025 Results
04:31pm, Thursday, 15'th May 2025
Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand. Gross profit increased 124% to $90.3 thousand.
60 Degrees Pharma survey suggests babesiosis affects up to 3M Americans—vastly more than CDC data—and may underlie millions of chronic fatigue cases.
